购物车

搜索结果

Search Results for " ig gamma-2a chain c region "

如果没找到您满意的产品或者您对产品有其他要求,可以联系我们专业顾问为您提供针对性的合理建议。     QQ咨询       网站留言咨询

提交您的定制咨询

点击图片重新获取验证码
Cat. No. Product Name Species Expression System
TMPJ-00893 IgG2a Protein, Rat, Recombinant

Ig γ-2A chain C...

Rat HEK293 Cells
Immunoglobulin G (IgG) is a type of antibody composed of four peptide chains—two identical heavy chains and two identical light chains arranged in a Y-shape typical of antibody monomers.There are four IgG subclasses (IgG1, 2, 3, and 4) in humans, named in order of their abundance in serum. The IgG2a isotype was able to interact very efficiently with FcgammaR, and share approximately 64-78% amino acid sequence identity with IgG1 and IgG2b in the heavy chain constant region domains, CH1, CH2 and C...
TMPK-01450 HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated

KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS...

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01456 HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)

KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01451 HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)

NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,...

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

重组蛋白

IgG2a Protein, Rat, Recombinant
Cat.No: TMPJ-00893
Species: Rat
Expression System: HEK293 Cells
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01450
Species: Human
Expression System: HEK293 Cells
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01456
Species: Human
Expression System: HEK293 Cells
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01451
Species: Human
Expression System: HEK293 Cells
TargetMol Loading
联系我们
400-820-0310

上海市静安区江场三路238号8楼